Literature DB >> 21963950

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.

Mauro S Malnati1, Silvia Heltai, Antonio Cosma, Peter Reitmeir, Simone Allgayer, Richard H Glashoff, Walter Liebrich, Eftyhia Vardas, Nesrina Imami, Samantha Westrop, Silvia Nozza, Giuseppe Tambussi, Stefano Buttò, Emanuele Fanales-Belasio, Barbara Ensoli, Fabrizio Ensoli, Antonella Tripiciano, Claudio Fortis, Paolo Lusso, Guido Poli, Volker Erfle, Harvey Holmes.   

Abstract

Delineation of the immune correlates of protection in natural infection or after vaccination is a mandatory step for vaccine development. Although the most recent techniques allow a sensitive and specific detection of the cellular immune response, a consensus on the best strategy to assess their magnitude and breadth is yet to be reached. Within the AIDS Vaccine Integrated Project (AVIP http://www.avip-eu.org) we developed an antigen scanning strategy combining the empirical-based approach of overlapping peptides with a vast array of database information. This new system, termed Variable Overlapping Peptide Scanning Design (VOPSD), was used for preparing two peptide sets encompassing the candidate HIV-1 vaccine antigens Tat and Nef. Validation of the VOPSD strategy was obtained by direct comparison with 15mer or 20mer peptide sets in a trial involving six laboratories of the AVIP consortium. Cross-reactive background responses were measured in 80 HIV seronegative donors (HIV-), while sensitivity and magnitude of Tat and Nef-specific T-cell responses were assessed on 90 HIV+ individuals. In HIV-, VOPSD peptides generated background responses comparable with those of the standard sets. In HIV-1+ individuals the VOPSD pools showed a higher sensitivity in detecting individual responses (Tat VOPSD vs. Tat 15mers or 20mers: p≤0.01) as well as in generating stronger responses (Nef VOPSD vs. Nef 20mers: p<0.001) than standard sets, enhancing both CD4 and CD8 T-cell responses. Moreover, this peptide design allowed a marked reduction of the peptides number, representing a powerful tool for investigating novel HIV-1 candidate vaccine antigens in cohorts of HIV-seronegative and seropositive individuals.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963950     DOI: 10.1016/j.jim.2011.09.005

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms.

Authors:  Marco Moroni; Silvia Ghezzi; Paolo Baroli; Silvia Heltai; Davide De Battista; Simone Pensieroso; Mariangela Cavarelli; Stefania Dispinseri; Irene Vanni; Claudia Pastori; Pietro Zerbi; Antonella Tosoni; Elisa Vicenzi; Manuela Nebuloni; Kim Wong; Hong Zhao; Sarah McHugh; Guido Poli; Lucia Lopalco; Gabriella Scarlatti; Roberto Biassoni; James I Mullins; Mauro S Malnati; Massimo Alfano
Journal:  J Transl Med       Date:  2014-12-05       Impact factor: 5.531

Review 2.  Scoping review of the applications of peptide microarrays on the fight against human infections.

Authors:  Arthur Vengesai; Maritha Kasambala; Hamlet Mutandadzi; Tariro L Mduluza-Jokonya; Takafira Mduluza; Thajasvarie Naicker
Journal:  PLoS One       Date:  2022-01-25       Impact factor: 3.240

3.  Multiplex peptide microarray profiling of antibody reactivity against neglected tropical diseases derived B-cell epitopes for serodiagnosis in Zimbabwe.

Authors:  Arthur Vengesai; Thajasvarie Naicker; Herald Midzi; Maritha Kasambala; Tariro L Mduluza-Jokonya; Simbarashe Rusakaniko; Francisca Mutapi; Takafira Mduluza
Journal:  PLoS One       Date:  2022-07-22       Impact factor: 3.752

4.  Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

Authors:  Nesrina Imami; Samantha J Westrop; Nathali Grageda; Anna A Herasimtschuk
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

5.  Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials.

Authors:  Sarah Kutscher; Claudia J Dembek; Simone Deckert; Carolina Russo; Nina Körber; Johannes R Bogner; Fabian Geisler; Andreas Umgelter; Michael Neuenhahn; Julia Albrecht; Antonio Cosma; Ulrike Protzer; Tanja Bauer
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.